Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of NVR 3-778 in Healthy Volunteers and Hepatitis B Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Healthy volunteers may be male or female between 18 and 65 years old with a BMI of 18-32kg/m2. They must be in good health not have any health condition which could interfere with the absorption, distribution or elimination of study drug, or with the clinical and laboratory assessments in this study.~Patients enrolling in Part II of the study, may be male or female between 18 and 65 years of age, with a BMI of 18-35kg/m2. Patients must have HBeAg positive, chronic hepatitis B with no history of clinical decompensation, and must not have been treated for hepatitis B before.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- NVR 3-778 (Type: EXPERIMENTAL): NVR 3-778 in varying doses of capsules by mouth for 1 day, 14 days, or 28 days
- Placebo for NVR 3-778 (Type: PLACEBO_COMPARATOR): Placebo for NVR 3-778 in varying doses of capsules by mouth for 1 day, 14 days, or 28 days
- NVR 3-778 and Pegasys (Type: EXPERIMENTAL): NVR 3-778 and Pegasys in combination in a yet to be determined dose by mouth and subcutaneous injection for 28 days
- Pegasys (Type: ACTIVE_COMPARATOR): Pegasys alone in a yet to be determined dose by subcutaneous injection for 28 days

Based on this trial design, predict the completion outcome and termination type (if applicable).